R&D: AstraZeneca invested in Canada
The British laboratory has announced an investment ” major “ in order to expand its R&D center in Mississauga (Canada), specializing in clinical studies in oncology – breast, lung and prostate cancer – in Covid-19 and in chronic kidney disease. AstraZeneca is also considering the creation of a new “AstraZeneca Rare Disease Development Hub” dedicated to its subsidiary Alexion for research into rare diseases. The total amount of the investment has not been specified. In all, no less than 500 positions will be created within these facilities.
“Our investment in AstraZeneca’s R&D center and Alexion’s development center will play a vital role in the development of new and innovative medicines to treat, prevent and, in the future, potentially even cure complex diseases like cancer and rare diseases », said Kiersten Combs, President of AstraZeneca Canada. Since 2019, the Mississauga R&D center has doubled in size, notably thanks to an investment of $135.6 million in 2021. The center is currently conducting more than 120 global clinical studies, involving patients in more than 50 countries.
VOS INDICES
source
CDMO: GTP Bioways will produce for Polygon Therapeutics
The Toulouse CDMO is committed to young Parisian biotech Polygon Therapeutics for the development of its flagship molecule, the first-in-class monoclonal antibody PLG-101. More specificly, GTP Bioways will be in charge of developing cell lines “unique, robust and scalable” intended for the large-scale industrial manufacture of the drug candidate.
“Our experienced team will develop the cell line in the first half of 2023, enabling Polygon to meet its deadlines. We will support Polygon with all documentation required for smooth clinical development”, said Eric Devic, CEO of GTP Bioways. Founded in January 2021, Polygon currently has only one compound in its pipeline. PLG-101 is still in the preclinical phase for the treatment of acute cardiovascular diseases related to the immune system. This antibody targets CD8+ T cells, a type of immune cell that plays a key role in the development of heart damage following myocardial infarction. With this collaboration, Polygon is preparing its progress towards the clinical phases.
Selected for you
